Tetracyclines, such as minocycline (MINO), are widely used in the treatment of infectious diseases. This combination therapy is expected to provide both antimicrobial and anti-inflammatory effects. Enhanced cytokine modulation by antibiotics may be a key mechanism in the treatment of severe infectious diseases such as JSF.

P3, N=610, Recruiting, Shenzhen Third People's Hospital | Not yet recruiting --> Recruiting

Microglia inhibition or depletion by treating organotypic cultures with minocycline or PLX3397 resulted in reduced levels of all the evaluated cytokines in the medium, confirming the role of microglia in the inflammatory microenvironment of glioblastoma. These findings provide valuable insights into how microglia interact with tumors and healthy cells in the tumor microenvironment, driving neuroinflammation and tumor cell dedifferentiation. This understanding could pave the way for the development of innovative therapies for glioblastoma.

P=N/A, N=100, Completed, Ain Shams Maternity Hospital

P=N/A, N=0, Withdrawn, Zimmer Biomet | N=108 --> 0 | Not yet recruiting --> Withdrawn

pinnata extract offers notable protection against kidney damage caused by gentamicin, mainly by enhancing the body's natural antioxidant defenses, decreasing lipid peroxidation, and maintaining the normal structure of kidney tissue. These findings suggest that A. pinnata could serve as a valuable complementary treatment to improve the safety of GM use.

We demonstrated that pioglitazone and minocycline protected against glutamate-induced axonal injury, rotenone-induced neuronal death and promoted oligodendrocyte differentiation. In summary, our findings demonstrate that human preclinical IPSC platforms can be used to characterize the neuroprotective properties of compounds and thus may aid the selection of drugs for clinical trials. Moreover, the platform's flexibility allows for the easy incorporation of additional disease-specific phenotypic assays.

This case illustrates the potential limits of monotherapy with beta-lactams in native joint infections caused by G. haemolysans, especially in immunocompromised patients. The failure of amoxicillin may be explained by factors such as limited diffusion into joint tissues, the absence of surgical debridement, and the use of pharmacokinetic and pharmacodynamic breakpoints not specifically validated for this rare species. Early reassessment and combination therapy may be warranted, particularly in immunocompromised individuals.

P4, N=1770, Active, not recruiting, Duke University | Trial completion date: Aug 2025 --> Dec 2025

P2, N=60, Completed, Novartis Pharmaceuticals

P3, N=1680, Recruiting, University of Oxford | Not yet recruiting --> Recruiting | Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Jul 2026

P=N/A, N=142, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Jan 2024 --> Dec 2026